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Abstract
Background
The Cervical Cancer Database of the Brazilian National Health Service (SISCOLO) con-
tains information regarding all cervical cytological tests and, if properly explored, can be
used as a tool for monitoring and managing the cervical cancer screening program. The aim
of this study was to perform a historical analysis of the cervical cancer screening program in
Brazil from 2006 to 2013.
Material and Methods
The data necessary to calculate quality indicators were obtained from the SISCOLO, a Bra-
zilian health system tool. Joinpoint analysis was used to calculate the annual percentage
change.
Results
We observed important trends showing decreased rates of low-grade squamous intrae-
pithelial lesions (LSIL) and high-grade squamous intraepithelial lesions (HSIL) and an
increased rate of rejected exams from 2009 to 2013. The index of positivity was maintained
at levels below those indicated by international standards; very low frequencies of unsatis-
factory cases were observed over the study period, which partially contradicts the low rate
of positive cases. The number of positive cytological diagnoses was below that expected,
considering that developed countries with low frequencies of cervical cancer detect more
lesions annually.
PLOS ONE | DOI:10.1371/journal.pone.0138945 September 24, 2015 1 / 11
OPEN ACCESS
Citation: Costa RFA, Longatto-Filho A, Pinheiro C,
Zeferino LC, Fregnani JH (2015) Historical Analysis
of the Brazilian Cervical Cancer Screening Program
from 2006 to 2013: A Time for Reflection. PLoS ONE
10(9): e0138945. doi:10.1371/journal.pone.0138945
Editor: Marcia Edilaine Lopes Consolaro, State
University of Maringá/Universidade Estadual de
Maringá, BRAZIL
Received: July 21, 2015
Accepted: September 5, 2015
Published: September 24, 2015
Copyright: © 2015 Costa et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: Data are available in
DATASUS (http://w3.datasus.gov.br/siscam/index.
php?area=0401).
Funding: The authors have no support or funding to
report.
Competing Interests: The authors have declared
that no competing interests exist.
Conclusions
The evolution of indicators from 2006 to 2013 suggests that actions must be taken to
improve the effectiveness of cervical cancer control in Brazil.
Introduction
Cervical cancer is the fourth most commonly diagnosed cancer in women worldwide, with an
estimated 528,000 new cases annually, and it is the fourth most common cause of cancer deaths
in women, with 266,000 estimated deaths annually. More than 85% of new cervical cancer
cases and more than 87% of the deaths from cervical cancer occur in developing countries [1].
In Brazil, cervical cancer, excluding non-melanomas, is the third most common cancer in
women, with an estimated incidence of 15.33 cases per 100,000 women. Cervical cancer is also
the third most common cause of cancer deaths among women in Brazil [2].
The lower incidence and mortality of cervical cancer in developed countries can be
explained by well-structured cytological screening programs and better medical infrastructure,
which are not frequently found in low- and middle-income countries [3].
The Brazilian Ministry of Health recognized the need for a national program for cervical
cancer control, and its coordination is the responsibility of the Brazilian National Cancer Insti-
tute (INCA) [4]. Brazilian health authorities recommend cytology-based screening at three-
year intervals for women between 25 and 64 years of age who have initiated sexual activity. In
recent years, multiple approaches to develop an effective cervical screening program have been
implemented in Brazil. In 2005, the Action Plan for the Control of Cervical and Breast Cancer
proposed six strategic guidelines: increased coverage of the target population, laboratory qual-
ity assurance, strengthening of the information system, professional training development,
social mobilization strategies and research development [4]. In 2012, to improve the quality
and reliability of cytopathological exams, a Quality Management Manual for Cytopathology
Laboratory was published by the Brazilian National Institute of Cancer and the Ministry of
Health. This manual presents some important indicators for the monitoring of laboratory
results, which assess overall and individual performance [5]. The Department of Informatics of
the Public Health System (DATASUS) created the Information System of Cervical Cancer
Screening (SISCOLO), which contains information regarding all Papanicolaou (Pap) tests col-
lected in the public health system. The SISCOLO was implemented for the management and
monitoring of the cervical cancer screening program [4] and is publicly available at http://
www2.datasus.gov.br/DATASUS/index.php.
Although the SISCOLO was implemented for monitoring and assisting in the management
of the above-mentioned program, this data resource has been poorly exploited and deserves
more attention. As a result, the present work is a historical analysis of the cervical cancer
screening program quality indicators in Brazil from 2006 to 2013 based on data collected from
the SISCOLO.
Materials and Methods
This is a time series study of the cervical cancer screening program quality indicators in Brazil.
Data regarding cytopathological exams (n = 81,322,700) were collected from the SISCOLO
according to the location of collection (Brazilian state) and age of the women who voluntarily
participated in the opportunistic Governmental Brazilian program of cervical cancer preven-
tion from 2006 to 2013. Data regarding the female population was obtained from the
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DATASUS from 2006 to 2012. All data collected from public access databases (SISCOLO and
DATASUS) are anonymous. This study was approved by the Ethics Committee of the Barretos
Cancer Hospital (identification: CAAE 26354114.0.0000.5437).
The following quality indicators were determined for women of 25 to 64 years of age: (1) pro-
ductivity rate; (2) percentage of exams performed during the target age (25–64 years); (3) posi-
tivity index (PI); (4) percentage of unsatisfactory exams; (5) percentage of rejected exams; (6)
ASC-US (atypical squamous cells of undetermined significance) percentage; (7) ASC-H (atypi-
cal squamous cells—high grade) percentage; (8) LSIL (low-grade squamous intraepithelial
lesion) percentage; (9) HSIL (high-grade squamous intraepithelial lesion) percentage; (10) ASC
(atypical squamous cell) percentage; (11) ASC/abnormal exam rate; and (12) ASC/SIL ratio.
The transformation zone (TZ) percentage, i.e., the percentage of scrubs with representation
of the transformation zone, was calculated for all women. This indicator was calculated for
women aged< 50 years and women aged 50 years.
The formulas used to calculate these indicators are presented in Table 1.
Processing of data and statistical analysis
All data were stored in.csv format, which allowed for management of the data using R software
(The R Foundations for Statistical Computing) and Microsoft Excel 2010 (Microsoft Corpora-
tion 2010). R software and Microsoft excel were used to organize the large volume of data from
the DATASUS and allowed for the creation of new spreadsheets.
Table 1. Formulas to calculate quality indicators and reference values.
Indicators Calculation Reference Values
General Productivity rate(a) number of exams performed ð25  64Þ
number of women ð25  64Þ  100 (a) Number of women unavailable for 2013
% Exams Performed in the target
age
number of exams performed ð25  64Þ
number of exams performed ðall agesÞ  100 Not available
Pre-
analytical
% Unsatisfactory number of unsatisfactory exams
number of exams performed ð25  64Þ  100 1% (Average of the collected exams in Brazil in 2010)
% Rejected number of rejected exams
number of exams performed ð25  64Þ  100 0.1% (Average of the collected exams in Brazil in 2010)
% TZ (50 years) number of TZ exams ð50Þ
number of satisfactory exams ð50Þ  100 50%
% TZ (<50 years) number of TZ exams ð<50Þ
number of satisfactory exams ð<50Þ  100 68%
Analytical % Positivity Index number of abnormal exams ð25  64Þ
number of satisfactory exams ð25  64Þ  100 3–10%
% ASC-US number of ASCUS exams ð25  64Þ
number of satisfactory exams ð25  64Þ  100 Not available
% ASC-H number of ASCH exams ð25  64Þ
number of satisfactory exams ð25  64Þ  100 Not available
% LSIL number of LSIL exams ð25  64Þ
number of satisfactory exams ð25  64Þ  100 Not available
% HSIL number of HSIL exams ð25  64Þ
number of satisfactory exams ð25  64Þ  100 0 5–1 0% (USA, 0.5%; Canada, 0.6%; UK, 1.1%; Norway,
1.1%)
% ASC number of ASC exams ð25  64Þ
number of satisfactory exams ð25  64Þ  100 <4–5%
ASC/Abnormal rate number of ASC exams ð25  64Þ
number of abnormal exams ð25  64Þ  100 <60%
ASC/SIL ratio number of ASC exams ð25  64Þ
number of SIL exams ð25  64Þ  100 <3
TZ, transformation zone; ASC-US, atypical squamous cells of undetermined signiﬁcance; ASC-H, atypical squamous cells cannot exclude high-grade
squamous intraepithelial lesion; ASC, atypical squamous cells; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial
lesion; SIL, squamous intraepithelial lesion.
(a) Number of women unavailable for 2013.
doi:10.1371/journal.pone.0138945.t001
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The annual percentage change (APC) for each indicator was calculated using the Joinpoint
Regression Program Version 4.1.1 (August 2014; Statistical Methodology and Applications
Branch, Surveillance Research Program, National Cancer Institute). Joinpoint analysis allows
for interpretation of changes over time to determine whether these changes are statistically sig-
nificant. Joinpoint software allows for adjustment of data series using a minimum number of
inflection points (zero, in which case the trend is represented by a single line segment) and
tests whether the inclusion of more inflection points (joinpoints) in the model has statistical
significance. To test for significance, the software uses the Monte Carlo permutations method,
and to determine the APC, the software uses the natural logarithm of the rates calculated using
the following formulas: y = mx+b, y = ln(rate) and x = calendar year, and APC = 100x(em-1).
The APC and estimates of the trend are used, with calendar year as the regression variable.
Each significant point indicates an increase or decrease in the rate [6]. To describe the linear
trend for each period, the APC values with 95% confidence intervals (95% CIs) are calculated
for each trend.
Results
From 2006 to 2013, 81,322,750 cytopathological exams were performed in Brazil, with
62,397,698 (76.7%) women within the screening target age range from 25–64 years.
Table 2 shows the distribution of exams according to Pap test results and age. Table 3 shows
the values for each indicator, and Table 4 shows the corresponding APC values. Figs 1 and 2
show the main results.
The productivity rate, positivity index and percentage of unsatisfactory exams remained rel-
atively stable over the entire study period. A yearly significant increase was observed in the per-
centage of exams performed on women in the target age range (APC = 0.8). Additionally,
Table 2. Number of exams according to Pap Smear results and age for Brazil 2006–2013.
Exams <25 years 25–64 years > 64 years Total
Performed 14,477,595 62,397,698 4,447,457 81,322,750
Satisfactory 14,307,468 61,668,690 4,372,053 80,348,211
Unsatisfactory 147,852 638,872 69,630 856,354
Rejected 22,336 94,162 6,527 123,025
Abnormal 545,726 1,596,740 126,390 2,269,856
TZ(a) 8,854,751 36,321,788 1,749,901 46,926,440
ASC-US 223,742 731,692 57,083 1,012,517
ASC-H(a) 17,416 115,732 14,726 147,874
ASC 241,158 847,424 71,809 1,110,391
LSIL 252,928 418,715 14,092 685,735
HSIL 26,144 185,695 16,912 228,751
SIL 279,072 604,410 31,004 914,486
AGC 11,153 83,557 5,826 100,572
AIS 18 359 33 410
SCC/ADC 1,138 15,366 5,963 22,467
TZ, transformation zone; ASC-US, atypical squamous cells of undetermined signiﬁcance; ASC-H, atypical squamous cells cannot exclude high-grade
squamous intraepithelial lesion; ASC, atypical squamous cells; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial
lesion; SIL, squamous intraepithelial lesion; AGC, atypical glandular cells; AIS, adenocarcinoma in situ; SSC, squamous cell carcinoma; ADC,
adenocarcinoma.
(a) Data collected from June 2006.
doi:10.1371/journal.pone.0138945.t002
Historical Analysis of the Brazilian Cervical Cancer Screening Program
PLOSONE | DOI:10.1371/journal.pone.0138945 September 24, 2015 4 / 11
Table 3. Values of the cervical cancer screening program quality indicators in Brazil 2006–2013.
Indicators Year
2006 2007 2008 2009 2010 2011 2012 2013
Productivity rate (%) 15.98 16.72 16.72 17.32 16.61 15.97 15.51 -
% Exams Performed 74.69 73.65 76.62 77.00 77.48 77.96 78.36 78.69
% Unsatisfactory 1.07 1.10 1.02 1.10 0.93 0.91 0.95 0.99
% Rejected 0.10 0.11 0.12 0.11 0.12 0.17 0.24 0.29
% TZ (50 years) 54.11 52.85 49.18 47.13 46.00 45.12 45.71 46.03
% TZ (<50 years) 66.83 67.74 66.92 65.37 65.12 64.07 64.91 64.94
% Positivity Index 2.64 2.57 2.50 2.48 2.62 2.64 2.59 2.72
% ASC-US 1.15 1.08 1.11 1.15 1.25 1.24 1.25 1.27
% ASC-H 0.17 0.18 0.18 0.18 0.20 0.21 0.22 0.24
% LSIL 0.82 0.76 0.69 0.64 0.66 0.67 0.63 0.54
% HSIL 0.33 0.31 0.30 0.29 0.30 0.30 0.30 0.27
% ASC 1.26 1.26 1.29 1.33 1.45 1.45 1.47 1.51
ASC/Abnormal rate (%) 47.77 49.02 51.78 53.48 55.19 54.77 56.58 55.52
ASC/SIL ratio 1.09 1.17 1.31 1.42 1.51 1.49 1.57 1.87
TZ, transformation zone; ASC-US, atypical squamous cells of undetermined signiﬁcance; ASC-H, atypical squamous cells cannot exclude high-grade
squamous intraepithelial lesion; ASC, atypical squamous cells; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial
lesion; SIL, squamous intraepithelial lesion.
doi:10.1371/journal.pone.0138945.t003
Table 4. APC values of quality indicators for Brazil 2006–2013.
Indicators Trend 1 Trend 2
Period Annual percent change CI 95% Period Annual percent change CI 95%
(APC) LL UL (APC) LL UL
Productivity rate (%) 2006–2009 2.4 -1.8 6.7 2009–2012 -3.6 -7.6 0.5
% Exams Performed 2006–2013 0.8 * 0.4 1.2
% Unsatisfactory 2006–2013 -2.1 -4.3 0.1
% Rejected 2006–2010 4.5 -5.1 15.0 2010–2013 35.4 * 16.3 56.6
% TZ (> = 50 years) 2006–2010 -4.4 * -6.0 -2.8 2010–2013 0.4 -2.2 3.0
% TZ (<50 years) 2006–2013 -0.7 * -1.1 -0.2
% Positivity Index 2006–2013 0.6 -0.5 1.7
% ASC-US 2006–2013 2.2 * 0.9 3.5
% ASC-H 2006–2009 2.1 -2.0 6.4 2009–2013 6.8 * 4.0 9.6
% LSIL 2006–2013 -4.6 * -6.6 -2.5
% HSIL 2006–2013 -1.8 * -3.2 -0.6
% ASC 2006–2013 3.0 * 2.1 3.8
ASC/Abnormal rate (%) 2006–2010 3.8 * 1.7 5.8 2010–2013 0.4 -2.7 3.6
ASC/SIL ratio 2006–2013 7.0 * 5.2 8.9
TZ, transformation zone; ASC-US, atypical squamous cells of undetermined signiﬁcance; ASC-H, atypical squamous cells cannot exclude high-grade
squamous intraepithelial lesion; ASC, atypical squamous cells; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial
lesion; SIL, squamous intraepithelial lesion; APC, annual percent change; CI, Conﬁdence Interval; LL, Lower Limit; UP, Upper Limit.
* The APC is signiﬁcantly different from 0 (p-value<0.05).
doi:10.1371/journal.pone.0138945.t004
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yearly significant increases in ASC-US percentage (APC = 2.2), ASC percentage (APC = 3.0)
and ASC/SIL ratio (APC = 7.0) and a yearly significant decrease in the percentage of LSIL
(APC = -4.6), percentage of HSIL (APC = -1.8) and percentage of TZ were observed in women
aged<50 years (APC = -0.7).
Finally, four indicators of quality showed one inflection point, indicating a change in the
trend; these indicators included the percentage of rejected exams, ASC-H percentage, rate of
ASC in abnormal exams and percentage of TZ in woman aged 50 years. The percentage of
rejected exams significantly increased (APC = 34.4) from 2010 to 2013; prior to 2010, this rate
was relatively stable. The ASC-H percentage remained stable until 2009 and then increased sig-
nificantly (APC = 6.8) until 2013. The ASC/abnormal exam rate increased significantly
(APC = 3.8) from 2006 to 2010, after which time it remained stable, and the percentage of TZ
in women aged50 years significantly decreased from 2006 to 2010 and then remained stable.
Fig 1. Historical description of the following indicators. (A) % exams performed (2006–2013: APC = -0.7 CI 95%: -2.1; 1.2). (B) % positivity index (2006–
2013: APC = 0.56 CI 95%: -0.5; 1.7). (C) % unsatisfactory (2006–2013: APC = -2.1 CI 95%: -4.3; 0.1). (D) % rejected (2006–2010: APC = 4.5 CI 95%: -5.1;
15.0) (2010–2013: APC = 35.4 CI 95%: 16.3; 56.6).
doi:10.1371/journal.pone.0138945.g001
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Fig 2. Historical description of the following indicators. (A) % ASC-US (2006–2013: APC = 2.2 CI 95%: 0.9; 3.5). (B) % ASC-H (2006–2009: APC = 2.1
CI 95%: -2.0; 6.4) (2009–2013: APC = 6.8 CI95%: 4.0; 9.6). (C) % LSIL (2006–2013: APC = -4.6 CI 95%: -6.6; -2.5). (D) % HSIL (2006–2013: APC = -1.8 CI
95%: -3.2; -0.6). (E) % ASC (2006–2013: APC = 3.0 CI 95%: 2.1; 3.8). (F) ASC/SIL (2006–2013: APC = 7.0 CI 95%: 5.2; 8.9).
doi:10.1371/journal.pone.0138945.g002
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Discussion
The SISCOLO is an important tool for improving the Brazilian opportunistic cervical cancer
program, as it contains a significant amount of data regarding Pap smear tests that can be used
to calculate quality indicators. Through these data, it is possible to identify fragilities and
strengths and to evaluate indicators to adjust the course of action. However, the SISCOLO infor-
mation has not yet been used at its maximum potential because it does not allow for the identifi-
cation of women or the calculation of the actual number of women who effectively underwent
Pap screening. In fact, the SISCOLO only provides the overall number of tests that were per-
formed. In addition, the SISCOLO data are only for women under the National Health System
(SUS) and do not cover women who use supplementary health services [7]. Indeed, when col-
lecting information from the SISCOLO, we noticed that some data were incomplete (e.g., 2013
data from Amapá state), and this may have been the result of the lack of a well-established flow
of information between institutions. In order to overcome some of the above-mentioned limita-
tions, the Brazilian Ministry of Health is implementing the Cancer Information System (SIS-
CAN) web platform, which integrates the information systems of cervical (SISCOLO) and
breast (SISMAMA) cancer screening programs. SISCAN will be associated with the National
Health Registry and will comprise a module to identify and convene women register in the SUS,
to carry out screening tests according to the periodicity and recommended age [8].
Focusing on the general results, we observed that the productivity rate, which is the ratio of
the number of Pap tests and the number of women in the target age range (25–64 years),
remained stable over the study period. If we consider the three-year interval of screening based
on the recommendation of the Brazilian guidelines, we observed a cumulative productivity rate
of approximately 45%. However, this number cannot be used as the real coverage rate, as a sig-
nificant number of women with a normal Pap test underwent screening more than once in a
three-year period [9, 10], possibly due to the overuse of Pap smears by physicians and a lack of
women’s knowledge of Pap test periodicity [11, 12]. In addition, approximately 25% of the
population had private health insurance [13], and the percentage of women who underwent a
Pap test at private health insurance laboratories is not included in the SISCOLO system. This
simple estimation showed that the Pap test coverage rate in Brazil is below 70%. The results
presented herein do not support those found in the Brazilian National Household Sample Sur-
vey (PNAD) performed in 2008, which reported a coverage rate higher than 80% over a three-
year period. PNAD is a research system that uses nationwide household data to produce basic
information to study the socioeconomic development of the country [14]. However, if we con-
sider that the productivity rate is an overestimation of the coverage rate and that we are count-
ing the number of exams rather than the number of women who underwent a Pap test, the
coverage rate appears to be lower than 70%.
Based on the percentage of exams performed on women in the target age range, the goal of
the cancer screening program was achieved, as there was a significant increase in this value
over the study period. However, approximately 25% of tests are performed on women outside
the target age range, which implies the existence of unnecessary financial resource consump-
tion. This high frequency of unnecessary exams outside the target population is frequently
observed in opportunistic programs [15–17], as in Brazil.
The analysis of the pre-analytical Pap test results showed that the percentage of unsatisfac-
tory exams did not vary over the study period, and importantly, this indicator follows the
World Health Organization (WHO) recommendation for unsatisfactory exams (<5%). How-
ever, the percentage of rejected tests significantly increased in recent years (2010–2013). This
result can be explained by the lack of care in handling, transportation and identification of sam-
ples, which underscores the importance of focusing not only on sample collection but also on all
Historical Analysis of the Brazilian Cervical Cancer Screening Program
PLOSONE | DOI:10.1371/journal.pone.0138945 September 24, 2015 8 / 11
of the steps between sample collection and sample analysis. Another important pre-analytical
indicator is the presence of epithelial cells from the transformation zone (TZ), as the presence of
these cells increases the likelihood of lesion identification, and the majority of lesions begin to
develop in this region [18–20]. Although the results showed that the percentage of TZ cells was
close to the Brazilian National Cancer Institute reference value, it significantly decreased over
the years, which may be a consequence of problems related to sample collection.
Regarding cytological alterations, the positivity indexes, which indicate the prevalence of
cell alteration and characterize the sensitivity of the screening process for detecting lesions,
were below those recommended by the Brazilian guidelines (3–10%) [5]. It is concerning that
these indexes are significantly below the indexes observed in developed countries, which have
already achieved control of cervical cancer incidence, such as Norway (4.9%) [21], the USA
(6.8%) [22] and Great Britain (6.5%) [23]. Interestingly, we observed a reduction in LSIL and
HSIL detection. The observed HSIL value was approximately 0.3% per year, which is below the
expected range (0.5–1.0%) [5] and below the values reported in developed countries, such as
the USA and Canada (0.5% and 0.6%, respectively) [24]. In addition, intraepithelial lesion
(LSIL and HSIL) detection rates significantly decreased over the study period, which may be
explained as a result of a complex network of events that could have limited the quality of
cytology-based screening. For example, prior to analyzing the results of Pap exams, events such
as inappropriate sample collection and slide preparation are likely to occur. Additionally, diffi-
culty in the detection of intraepithelial lesions by cytotechnologists and/or cytopathologists can
occur as a consequence of suboptimal slide preparation, high workload routine, limitations
related to the continued education of the professionals or even inadequate training of the pro-
fessionals. Conversely, this decrease may also be explained by a real reduction in the prevalence
of intraepithelial lesions in the population; however, the high ASC-US and ASC-H percentages,
which have been found to be increasing, support the first hypothesis of problems in the collec-
tion phase and/or the interpretation of the samples. This result highlights the need for better
training of the professionals who collect and analyze these samples.
In general, the pre-analytical and analytical phase indicators suggest a suboptimal Pap test
performance, which could be attributed to the low professional efficiency in the collection,
preparation and reading of the samples. To maintain an adequate level of competence, it is
important that the laboratory processes a minimum number of samples per year. In this con-
text, the Pan American Health Organization (PAHO) considers it essential that a laboratory
process at least 15,000 exams annually [25]. However, according to a study conducted in Brazil
in 2002 on 739 participating laboratories, only 18.9% of the laboratories had performed at least
15,000 exams/year [26], suggesting that the majority of laboratories may be working with
examiners who have not adequately developed their skills.
Even laboratories that perform a large amount of exams can show poor indicators due to
excessive overload. As elegantly reported by Renshaw and colleagues, the reading of more than
50 slides per day (6 hours of work) initiates an ascendant curve of progressive errors related to
fatigue and loss of attention [27]. This variable is far from being controlled in many Brazilian
laboratories. In fact, the low price of Pap tests paid by the Government (circa US $2.0) pushes
cytotechnicians to examine more than the recommended 50 slides per day. This fact generates
a pernicious circle resulting in cytotechnicians getting paid less to analyze more slides than
recommended.
Despite the above-mentioned limitations of the current screening program, it is important
to note that the increase in access to Pap tests has been associated with a decrease in cervical
cancer-related mortality, which has been observed in developed regions in Brazil (South,
Southeast and Midwest). However, this success is only partial, as the underdeveloped regions
(North and Northeast) have experienced an increase in cervical cancer-related mortality [28].
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Based on the findings of the present study and according to the optimal quality control mea-
sures, the government should invest more funds in internal quality control during both the
pre-analytical phase, via review of the adequacy of collection, fixation and transportation of
samples to the laboratory, and the analytical phase, via the training of cytotechnologists to
improve their professional skills. Additionally, as some studies show the importance of external
quality control of laboratories in the improvement of professionals’ skills in detecting cervical
cancer precursor lesions, a systematic improved external control should be implemented at all
cytopathology laboratories that provide services to the public health system. The current exter-
nal system of quality control implemented by the Brazilian Government is limited to a small
number of samples in selected laboratories examined periodically [29, 30], which may result in
an unrealistic panorama of the laboratories’ performances.
Importantly, one should also keep in mind the recent breakthrough in cervical cancer pre-
vention due to the introduction of human papillomavirus (HPV) vaccines. This event promises
to modify the burden of cervical cancer incidence and mortality. However, as the vaccines only
protect against oncogenic HPVs, which are responsible for approximately 70% of all cervical
cancers, it is important to increase the sensitivity and reproducibility of the screening program.
In this regard, HPV DNA testing combined or followed by Pap smear test in HPV-positive
cases is as an attractive approach for cervical cancer screening in the present scenario [31].
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